Ismael Macias Declara
@MaciasDeclara
Followers
316
Following
2K
Media
26
Statuses
241
Medical Oncologist MD, PhD. Hospital Clínic de Barcelona. 🏥 @hospitalclinic @idibaps Gastrointestinal and neuroendocrine tumors
Barcelona, Spain
Joined February 2022
📣 ¡Arranca la campaña #IluminaEnVerde26! Después del éxito conseguido en 2025 con 150 edificios y monumentos iluminados en todo el país, ¡volvemos a encender la esperanza! 💪 El próximo 19 de febrero de 2026, Día Mundial del Colangiocarcinoma, queremos superar esa cifra y dar
0
4
7
🔵Preoperative PAXG vs mFOLFIRINOX for R or BR pancreatic cancer Full publ. of CASSANDRA trial @TheLancetOncol ➡️PAXG: cisplatin, nab-paclitaxel, capecitabine, and gemcitabine ➡️Design👇 ✅EFS: 16 vs 10.2 mo HR: 0.63 [0.47–0.84]; p=0.0018 ✅G3-4 AE: 66% vs 61% ⏰OS is
2
50
99
En dia mundial del càncer de pàncrees reafirmem el nostre compromís amb la recerca i l’atenció de qualitat a les persones afectades. Continuem treballant en equip per millorar el pronòstic i l’esperança. 🔬💜 @hospitalclinic @idibaps
0
5
44
Terrific review on evolving treatment strategies for resectable gastric cancer.
🚨 Just out in Cancer Treatment Reviews! Proud to share our review: “Evolving treatment strategies for resectable gastric cancer: Bridging Asia–West disparities toward personalized and integrated therapy.” 👉 https://t.co/wiE7qo4lej
@hospitalclinic @idibaps @VHIO
0
0
0
Representation of the Medical Oncology Department of @hospitalclinic. Proud of our team and our commitment to excellence in patient care, research, and education. #Oncology #HospitalClínic @idibaps @myESMO #ESMO25
2
11
78
Hepatic Arterial Infusion Pump Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma 🔎PUMP-2 Trial @JCO_ASCO
https://t.co/EMwfTeeo8Z 👉48 pts HAIP floxuridine + CTx 👉PR: 44%; DCR: 84% 👉1-year OS: 80.0% 🧐strong signal, interesting opportunity for downstaging,
1
21
73
Excelente iniciativa de @ACTEG_ para fomentar la formación multidisciplinar en tumores gastroesofágicos. 👩⚕️👨⚕️ Dirigido a residentes de cualquier especialidad implicada. 📅 Fecha límite: 14/11/2025 🔁 ¡Animad a vuestros residentes a participar!
📢 I Concurs de casos clínics en tumors gastroesofàgics (ACTEG) 👩⚕️ Per a residents de qualsevol especialitat implicada. 🏆 Premi: inscripció a congrés. ⏰ Data límit: 14/11/2025 📧 mimallafre@clinic.cat
0
0
3
✨ A true pleasure to be part of this amazing little big family.
The picture reflects the Tumor Board held yesterday. It displays the involvement of several disciplines to reach optimal decisions for individual patients. A complex disease requires blending evidence with individual profile. The CUSE concept,
0
0
3
📚 La millor manera de créixer com a comunitat científica és compartir experiències i coneixement. Ens hi veiem!
📢 El 9 d’octubre al Hospital de Granollers State-of-the-Art Management of Localized Esophagogastric Tumors 🔹 Taules rodones interactives 🔹 Highlights científics 🔹 Debat multidisciplinari 🕠 17:30-20:00h 📩 Inscripcions: mimallafre@clinic.cat @HelenaVerdaguer
0
3
7
👉 Particularly interesting to see so much focus on biliary and pancreatic cancers at #ESMO25. @myESMO @_SEOM @GrupoTTD
📢Biliary tract, HCC and pancreatic cancers oral abstracts in #ESMO25 @myESMO 👇 😍There are a lot of oral upper GI abstracts in #ESMO25. I am sure that some are practice-changing but all will give very important insights for practice! #cancer #oncology #GI #biliary
0
1
6
Hoy recordamos a quienes olvidan y acompañamos a quienes cuidan. 💜 #DíaMundialDelAlzheimer
0
0
6
🔬 Avui s’han celebrat les III Jornades d’ACTEG-SCBO: actualització multidisciplinària en diagnòstic, teràpies i reptes clínics. Gran fòrum per compartir avenços amb oncòlegs mèdics i radioteràpics, cirurgians, patòlegs, endoscopistes. #ACTEG #SCBO #TumorsDigestiu #Oncologia
0
7
13
Falten dos dies! No us ho perdeu! @cpericay @chierrocarbo @oncolvisa @TamaraSN2 @dmomblan @mariglesiascoma @DrNotarioR @RobertMontal @DanielAcostaEy1 @EduardoTB94 @CalvoMariona @PaulaCerd1 @HelenaVerdaguer @OncoTauli
📢 III Jornada ACTEG-SCBO 🗓️ 19/09/2025, 9:30–13:30 📍 Seu SCBO, Barcelona Jornada científica sobre tumors esòfag-gàstrics: 🔹 Actualització ACTEG-SCBO 🔹 Debats de casos reals 🔹 Visió multidisciplinària ℹ️ Programa i inscripcions: mimallafre@clinic.cat
0
8
9
¿Eres oncólogo médico interesado en cáncer urológico? Quizás te interesa trabajar y desarrollar tu carrera con nosotros en el @hospitalclinic . Escríbeme y comentamos los detalles
0
4
3
👉 Promising data in 1L advanced biliary tract cancer with tislelizumab + ociperlimab + GemCis: ORR 51%, mOS 17.4 mo, though with relevant toxicity. 🔜 Phase III confirmation needed.
🟤Tislelizumab + ociperlimab +GemCis in 1L treatment of advanced biliary cancers ZSAB-TOP ➡️PD-1/PD-L1 and TIGIT ➡️41 pts, phase 2 , 75% iCCA ✅ORR: 51.2% ✅mPFS: 7.7 mo ✅mOS: 17.4 mo 😮 ❗️AE ≥G3: 60% ➡️Looks promising, phase III RCT is needed 👉 https://t.co/jx6lYC2qAl
0
0
2
🌱 4 meses desde el “nacimiento” de la idea 🥳 11-Sept-2025- la primera reunion del “Comité Nacional de Tumores Biliares” 😊 Encantada de vez a tanta gente conectada. Mil gracias a todos por el entusiasmo. 👉 A los interesados: https://t.co/oOoHf2c2Ao 🤔 Que es CNTB? - 🧵
A 🤩 idea was born today 💡🌱🤞🏻🫂 Tips: #BiliaryMalignancies #Spain #BestCare Name being polished 🤔 Will keep you all posted 😉 @atuvibi @cofiadeva @MacarullaTeresa @mponzsar @anavivancob @AnaVivancosVHIO and others… 👇 And more people to come (hopefully)
3
12
46
🔄 mFOLFIRINOX vs Gem/Nab-P: no clear winner, same outcome
🟠mFOLFIRINOX vs Gem/Nab-Paclitaxel in 1L treatment of metastatic pancreatic cancer PASS-01 @JCO_ASCO ❌mPFS: 4 vs 5.3 mo HR: 1.37 [0.97 to 1.92]; P = .069 ✅mOS: 8.5 vs 9.7 mo HR: 1.57 [1.08 to 2.28]; P = .017 ➡️In line with the results of GENERATE trial from Japan 🤔 Does
0
1
2
Cita obligatoria @dmomblan @oncolvisa @chierrocarbo @cpericay @TamaraSN2 @mariglesiascoma @DrNotarioR @RobertMontal @EduardoTB94 @DanielAcostaEy1 @CalvoMariona @PaulaCerd1 @HelenaVerdaguer @OncoTauli
📢 III Jornada ACTEG-SCBO 🗓️ 19/09/2025, 9:30–13:30 📍 Seu SCBO, Barcelona Jornada científica sobre tumors esòfag-gàstrics: 🔹 Actualització ACTEG-SCBO 🔹 Debats de casos reals 🔹 Visió multidisciplinària ℹ️ Programa i inscripcions: mimallafre@clinic.cat
0
5
4
🙌🏽 I can't agree more @GIMedOnc 🤯 What an amazing work @NatureMedicine 💥 Phase I AMPLIFY-201: ELI-002 (KRAS vaccine) 🧪 immunogenic in MRD+ PDAC/CRC 📌 84% had KRAS-specific T-cell responses ✅ mRFS 16.3mo ✅ OS 28.9mo #Immunotherapy #tragetedtherapy #Oncology
@OncoAlert
Hot off the presses, probably my favorite interventional paper of 2025 (doesn't hurt that I look up to several of the authors as mentors or role models). 💉RAS vaccination is starting to look less like fantasy, more like reality. 🆕 Nature Medicine | Wainberg et al 🎯
0
7
17
Gastric cancer @TheLancet
https://t.co/wjuz9H4LWn 👏Excellent and comprehensive summary from screening to targeted therapies by @sundar__raghav @LizzySmyth1 @YJanjigianMD @KoheiShitara @HannekevanLaar1
@myESMO
0
84
215